Please wait...

You selected inventions in category Life Sciences

  • NATURAL MOLECULES EXTRACTED FROM BERGAMOT TISSUES EXTRACTIONNATURAL MOLECULES EXTRACTED FROM BERGAMOT TISSUES...
      Preview
      Description

      DESCRIPTION
      The present innovation regards the description, extraction and pharmaceutical use of a natural compound present in Citrus fruit, in particular in Bergamot. It has a flavonoidic structure linked to hydroxymethyl glutaric acid. The statin-like structure allows its potential use as anticholesterol active principle.

      ADVANTAGES
      The extraction of the statin-like drug may be obtained from very abundant natural products, by green processes, thus avoiding chemical synthesis.
      The commercial available statins produce side-effects on the patients. The natural potential drug, besides the proved anticholesterolemic effect, releases a flavonoidic moiety of known antioxidant properties The natural compound is extracted from the pulp of citrus fruit like bergamot that in most cases is a waste product of the perfumery industries related to essential oil. The natural statin-like drug claimed in this patent application, is directly available from citrus fruits. The commercially available statins require a multi-step synthetic procedures, thus the use of chemical reagents, solvents, waste delivering problems, etc., which inevitably rises the production costs. The new proposed statin-like drug is a natural product, already experienced in local folk medicine without any apparent drawback, therefore it is expected to meet the consumers needs.

      APPLICATION
      Replacing anti-cholesterol synthetic drugs with natural products having similar benefit. The technology may have Pharmaceutical and nutraceuticals applications.

      INNOVATIONS FEATURES
      It is the first natural statin-like active principle that could be used in cholesterol related diseases.

      STAGE OF DEVELOPMENT
      Reduction to Practice/Prototype (in vivo experiments)

      Full details Contact close
    • METHOD AND DEVICE FOR MEASURING CIRCULAR DICHROISM IN REAL TIMEMETHOD AND DEVICE FOR MEASURING CIRCULAR...
        Preview
        Description

        DESCRIPTION
        The present invention relates to a method and a device to measure the circular dichroism exploiting a diffraction grating with proper polarization properties.
        The grating generates first orders diffraction beams whose amplitudes are proportional to the left and right circular components of the incident light beam. We demonstrate that, exploiting this feature of the grating, the circular dichroism of any system can be easily evaluated measuring only the intensities of the first order diffracted beams, just locating the grating after the investigated system.

        APPLICATION
        Pharmaceutical, biological , cosmetic , food and environmental sector.

        ADVANTAGES
        -The method is based on the use of a single element, no other optical elements (prisms, mirrors, waveplates etc.) are required, implying low losses and reducing artefacts;
        -No monochromator and phase sensitive detectors are required;
        -No moving or modulated elements are present;
        -No detection of the light beam intensity before the sample is needed since, exploiting the particular diffraction properties of the grating, the analysis is performed on the transmitted (diffracted) light beams;
        -White linear polarized or rotating linear polarized or depolarized light can be used,
        -The dispersive properties of the grating allow to perform real time measurements, since the signal at any wavelength is diffracted at different angles from the grating and can be revealed in parallel by a photodiode array or a CCD;
        -The previous described properties allows to investigate dynamical processes;
        -Complex and repetitive calibration procedure are not required;
        -Small size , the device can be used for “in situ” measurements and integrated into in-line instruments;
        -Compact device allow to made a portable version of the instrument;
        -Reduction of the production costs.

        STAGE OF DEVELOPMENT
        Working prototype.

        Full details Contact close
      • MONOSPECIFIC ANTIBODY AND METHOD OF PRODUCTION USING ASMONOSPECIFIC ANTIBODY AND METHOD OF PRODUCTION...
          Preview
          Description

          DESCRIPTION
          Antibody and method of production of antibodies obtained using as antigen an isoform of the human FAD synthetase, obtained by means of technology of recombinant DNA cloned and overexpressed in microorganisms cultures in particular a colony of E. coli Rosetta (DE3) cells, in which said antigen is purified and concentrated by means of electrophoresis and extraction in tampon before being inoculated in the test animal.

          APPLICATION
          -Biotecnology, the procaryotic and eucaryotic cells use the FAD as co-maker of hundreds of different flavoenzym.es with dehydrogenasic and oxydasic activities. These are involved in the terminal metabolism, in the processes of energetic transduction, in protection from the cellular stress, in folding of the secretion protein, in the independent caspase apoptosis, in the chromatin remodeling processes, etc.
          -Molecular diagnostics, in order to clarify the aspects of the FAD synthetase cellular biochemistry not yet solved (expression variations, other isoforms existence, tissues specificity, organs specificity etc) .The usage of the antibody will be useful to measure the nutritional state of flavine co-factors in different tissues and, in particular, it could have high diagnostical value for the identification of the FAD synthetase in the thyroid tissues and its quantification in the hypothyroidism.
          There exist human pathologies which could be caused by the deficiency of the FAD synthetase protein, like the RR-MADD, which if it is diagnosticated in time can be treated with the simple ingestion of riboflavine in high doses. The antiserum would permit the monitoring of the human protein.

          ADVANTAGES
          Up to nowadays the measuring of the FAD synthetase activity was conducted with spectrofluorimetric techniques in enzymatic catalytic in continuo dosages which realization requests time for samples preparation and specific competences of enzymatic kinetics. As an alternative, high resolution liquid chromatography, a technique which requests, first of all, the usage of sophisticated and dear apparatuses, is used. The production of an antibody obtained from the FAD synthetase antigen permits a rapid and simple research of the alterations of the same FAD synthetase usable in immuno-electrophoretic or immuno-enzymatic applications.

          INNOVATIONS FEATURES
          Represents the only molecular test available for the identification of the human and the rat's FADsynthetase protein.

          STAGE OF DEVELOPMENT OF THE TECHNOLOGY OFFER
          Product, sample of protein available (30 ml)

          INTELLECTUAL PROPERTY STATUS
          -US patent GRANTED
          -EUROPEAN patent application (Positive International Search Report)

          OWNER: University of Calabria

          Full details Contact close
        • Detection of causative agents of ocular and nervous system infectionsDetection of causative agents of ocular and...
            Preview
            Description

            The present technology is related to diagnosis method for detection of single or more causative agents of ocular and nervous system infections among many probable pathogens. The invention provides a rapid assay for the simultaneous detection of the pathogens responsible for infections of the eye and central nervous system for which immunological parameters are not indicative of an active infection but only indicative of exposure to the pathogen and for which classical microbiological assays such as bacterial and fungal cultures are neither sensitive enough to detect the pathogen nor rapid enough to identify the pathogen within 48 hours. In addition aqueous humor or vitreous fluid in case of endophthalmitis will be sufficient in order to detect and discriminate the infectious agent. This obviates the necessity of surgical procedure such as vitrectomy to be performed in an operating room.

            This technology combines the high sensitivity of PCR assay and the high specificity of identification by hybridization on to a macro-array with the detection of hybridization by color detection methods, the end result of which can be monitored by naked eye.

            The invention features a multiplex assay for the simultaneous detection and discrimination of pathogens that cause infections of the eye and CNS comprising:

            1) Processing the clinical samples such as corneal scraping or conjunctival swab or aqueous humor or vitreous fluid or vitrectomy lavage collected or cerebrospinal fluid aspirate or pus collected from brain abscess material or an epiretinal membrane from a patient suspected of being afflicted with eye or a CNS infection, to isolate DNA by standard methods.
            2) Amplifying a specific region of DNA from a gene that is specific to each of the pathogens by a single tube PCR technique using labeled amplification primers for each of the pathogens known to cause CNS and eye infections
            3) Detection and discrimination of pathogens using a DNA hybridization wherein the immobilized target sequences specific for each of the pathogens are reacted with amplified DNA probes generated from the PCR reaction and monitoring the hybridization by color development using specific set of reagents.

            Full details Contact close
          • Nanoparticle for drug deliveryNanoparticle for drug delivery
              Preview
              Description

              The technology suggests a sustained-release nanoparticle composition composed of a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol conjugate for preventing or treating a disease or a condition. The said nanoparticle composition further contains a therapeutic agent such as an antibiotic, anti-restenotic agent, anti-proliferative agent, anti-neoplastic, chemotherapeutic agent, cardiovascular agent, anti-inflammatory agent, immunosuppressive agent, or anti-tissue damage agent. Such nanoparticle compositions generally have a diameter in the range of 20 nm to 100 nm and are used locally for the prevention or treatment of diseases or conditions.
              The said technology also suggests a method for using a sustained-release nanoparticle composition for preventing or treating a disease or condition. The preclinical studies of this technology have been performed on animal model (rat).

              Full details Contact close
            • Process of Preparation of nanoparticles for drug delivery systemProcess of Preparation of nanoparticles for drug...
                Preview
                Description

                The present invention is related to a process for the preparation of the novel nanoparticles of apotransferrin / transferrin which are useful for the preparation of a pharmaceutical composition facilitating easy delivery of the drug.
                What is Novelty
                • Prior methods uses the cross linking of apotransferrin with the bioactive compound where cross linking reduce drug efficacy and removal of cross linking is rate limiting. While in present invention apotransferrin has not cross linked with bioactive material and hence the release of bioactive material may not be rate limiting and become instantaneous and release into the cell.
                • Present invention provides a non-toxic delivery system.

                Full details Contact close
              • Detection kit for Sexually transmitted diseasesDetection kit for Sexually transmitted diseases
                  Preview
                  Description

                  The present technology provides a multiplex PCR based prototype kit for detection of the Chlamydia trachomatis and Neisseria gonorrhoeae, based on designed primers. The kit contains all the reagents for collection of clinical samples, for carrying out amplification by PCR and the detection of the product, as well as the protocol to be used for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in patient samples. The kit also provides a new transport medium that is not only suitable for collecting the sample but also storing the sample at 4°C for several days. An internal control has also been designed against human gene to test for any PCR inhibition in the sample.

                  Full details Contact close
                • Herbal remedy to prevent atherosclerosisHerbal remedy to prevent atherosclerosis
                    Preview
                    Description

                    This technology suggests an herbal preparation for prevention of atherosclerosis and hyperlipidemia. The said preparation is anti-inflammatory anti oxidant and increases serum HDL and more specifically it inhibits Lox-15, cox-2 and Ca deposition in the plaque, increases collagen in the chronic plaque, increases serum HDL and decreases serum TG. This herbal preparation contains mixer of Commiphora mukul, Bosewellia, Semecarpus anacardium, Strychnos nux vomica, Terminalia arjuna, Shankha, Rubia cordifolia, Bacopa monnieri, Triphala and Trikatu. Male rabbits have been used for preclinical studies.
                    What is Novelty?
                    • There is no single medicine which can prevent atherosclerosis and hyperlipidemia
                    • To manage this disease patient has to take several medicines, which leads to psychological depression while present technology in the form of single tablet to cure atherosclerosis and hyperlipidemia
                    • This medicine does not have any side effects

                    Full details Contact close